title: A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray.
abstract: BACKGROUND
  Topical nasal corticosteroids have become a mainstay of treatment for the symptoms of seasonal allergic rhinitis (SAR). It is likely that topical corticosteroids, by blocking an initial influx of inflammatory cells in the nasal mucosa induced by aeroallergens, may have a preventive effect on nasal allergy symptoms when administered before the pollen season.
  
  
  OBJECTIVE
  This study was designed to assess the efficacy and safety of an 8-week course of mometasone furoate nasal spray (MFNS), 200 micrograms once daily, in the treatment of SAR compared with beclomethasone dipropionate aqueous nasal spray (BDP), 168 micrograms twice daily, and placebo vehicle, when treatment is initiated before the anticipated onset of the ragweed season.
  
  
  METHODS
  Three hundred forty-nine patients with SAR to ragweed pollen from nine centers in the Northeast and Midwest of the United States were randomized to one of the three intranasal study medications (MFNS, 200 micrograms once daily, BDP, 168 micrograms twice daily, or placebo vehicle), starting 4 weeks before the estimated start of the ragweed season.
  
  
  RESULTS
  The proportion of "minimal symptom" days (total nasal symptom score < or = 2) was statistically significantly higher in both the MFNS and BDP groups when compared with the placebo vehicle group (p < 0.01). The two active treatment groups were not statistically significantly different from each other. MFNS and BDP displayed a similar safety profile that did not differ from placebo.
  
  
  CONCLUSIONS
  This suggests that MFNS, 200 micrograms (once daily), is a useful therapy in the prophylactic treatment of SAR.
authors.affiliation: Park Nicollet Clinic, Minneapolis, USA.
authors.forename: D
authors.initials: D
authors.lastname: Graft
authors.forename: D
authors.initials: D
authors.lastname: Aaronson
authors.forename: P
authors.initials: P
authors.lastname: Chervinsky
authors.forename: H
authors.initials: H
authors.lastname: Kaiser
authors.forename: J
authors.initials: J
authors.lastname: Melamed
authors.forename: A
authors.initials: A
authors.lastname: Pedinoff
authors.forename: J P
authors.initials: JP
authors.lastname: Rosen
authors.forename: E J
authors.initials: EJ
authors.lastname: Schenkel
authors.forename: M L
authors.initials: ML
authors.lastname: Vandewalker
authors.forename: A
authors.initials: A
authors.lastname: Keim
authors.forename: P K
authors.initials: PK
authors.lastname: Jensen
authors.forename: K
authors.initials: K
authors.lastname: Nolop
authors.forename: B
authors.initials: B
authors.lastname: Mesarina-Wicki
mesh_terms: D000281:Administration, Intranasal; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001507:Beclomethasone / Q000008:administration & dosage / Q000009:adverse effects; D004311:Double-Blind Method; D005938:Glucocorticoids; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000008:administration & dosage* / Q000009:adverse effects; D006255:Rhinitis, Allergic, Seasonal / Q000517:prevention & control*
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D001507:Beclomethasone